Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111927" target="_blank" >RIV/00843989:_____/25:E0111927 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/25:A2603DOR

Výsledek na webu

<a href="https://doi.org/10.1002/ejhf.3787" target="_blank" >https://doi.org/10.1002/ejhf.3787</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.3787" target="_blank" >10.1002/ejhf.3787</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase

Popis výsledku v původním jazyce

In heart failure with reduced ejection fraction (HFrEF), mineralocorticoid receptor antagonists (MRAs) reduce mortality and HF hospitalizations, and are one of the key cornerstones of guideline-directed medical therapy. Hyperkalaemia (or fear of hyperkalaemia) is a major reason for their underuse. In the randomized-withdrawal phase of the REALIZE-K trial, of patients with HFrEF and prevalent hyperkalaemia or at risk of hyperkalaemia, continued use of the potassium (K+) binder sodium zirconium cyclosilicate (SZC) led to large increases in the number of participants on optimal-dose spironolactone with normokalaemia, and reduced the risk of hyperkalaemia and down-titration/discontinuation of spironolactone compared with withdrawal to placebo. Prior to the placebo-controlled, randomized-withdrawal phase of REALIZE-K, there was a run-in phase in which SZC was used to manage hyperkalaemia and spironolactone dose was optimized. This analysis evaluated the efficacy of SZC in lowering serum (s)K+ and enabling SZC titration during the run-in phase among those with prevalent hyperkalaemia on no or low-dose (12.5 mg) spironolactone; and in those identified as at high risk of hyperkalaemia on no or low-dose spironolactone, to evaluate the incidence of hyperkalaemia during spironolactone dose titration during the run-in phase and use of SZC to lower sK+ and enable maintenance of spironolactone.

Název v anglickém jazyce

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase

Popis výsledku anglicky

In heart failure with reduced ejection fraction (HFrEF), mineralocorticoid receptor antagonists (MRAs) reduce mortality and HF hospitalizations, and are one of the key cornerstones of guideline-directed medical therapy. Hyperkalaemia (or fear of hyperkalaemia) is a major reason for their underuse. In the randomized-withdrawal phase of the REALIZE-K trial, of patients with HFrEF and prevalent hyperkalaemia or at risk of hyperkalaemia, continued use of the potassium (K+) binder sodium zirconium cyclosilicate (SZC) led to large increases in the number of participants on optimal-dose spironolactone with normokalaemia, and reduced the risk of hyperkalaemia and down-titration/discontinuation of spironolactone compared with withdrawal to placebo. Prior to the placebo-controlled, randomized-withdrawal phase of REALIZE-K, there was a run-in phase in which SZC was used to manage hyperkalaemia and spironolactone dose was optimized. This analysis evaluated the efficacy of SZC in lowering serum (s)K+ and enabling SZC titration during the run-in phase among those with prevalent hyperkalaemia on no or low-dose (12.5 mg) spironolactone; and in those identified as at high risk of hyperkalaemia on no or low-dose spironolactone, to evaluate the incidence of hyperkalaemia during spironolactone dose titration during the run-in phase and use of SZC to lower sK+ and enable maintenance of spironolactone.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European journal of heart failure

ISSN

1388-9842

e-ISSN

1879-0844

Svazek periodika

27

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

1491-1495

Kód UT WoS článku

001554516500001

EID výsledku v databázi Scopus

2-s2.0-105013796832